Tailoring Inhaled Corticosteroids in patients with Severe Asthma taking Biologics
Severe asthma patient on either dupilumab or tezepelumab
Participants will already be established on asthma biologic medications (either dupilumab or tezepelumab). Will will be on maximal maintenance and reliever inhaled therapy (Fostair NEXTHaler 100/6 4 puffs BD) and reduce their MART dose as able during the study (between 2 and 8 puffs daily) over a 6 month period. They will undergo airway oscillometry, spirometry, mannitol challenge, blood tests, FeNO and questionnaires to assess symptom control and quality of life at 3 visits (including a screening visit).
1. Any patient over 18 years of age with severe asthma taking dupilumab or tezepelumab for severe asthma for at least 6 months 2. FEV1 ≥50% at baseline
1. Any patients on maintenance oral steroids or required an oral steroid burst in the past 28 days 2. Any patient who was switched from another biologic in the past 3 months 3. Any other respiratory condition such as moderate to severe bronchiectasis or COPD 4. Currently pregnant